RG6392 / Roche - LARVOL DELTA

Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers. (PubMed, Front Immunol) - "These findings aid the design of dosing regimens of RO7497987 as an immunomodulatory agent. https://www.isrctn.com/ISRCTN92655801, identifier ISRCTN92655801."

Clinical • Journal • P1 data • Musculoskeletal Pain • Pain • FLT3 • FLT3LG